Lack of Tissue Virological Response as a Predictor of Relapse in Chronic Hepatitis D after Completion Bulevirtide Therapy

Aim: to evaluate the significance of a positive polymerase chain reaction result for hepatitis D virus RNA (HDV RNA) in liver biopsy specimens of patients with chronic hepatitis D (CHD) after completion of antiviral therapy (AVT) as a predictor of infection relapse.

Materials and methods. The study included 21 patients with CHD who received combined AVT with peginterferon alpha and bulevirtide for 48 weeks, followed by bulevirtide monotherapy for 48–96 weeks, making the total duration of antiviral therapy 96–144 weeks. In all patients HDV RNA became undetectable in serum 24–96 weeks from the start of treatment, with aviremia maintained for at least 48 weeks until the end of AVT. At the end of treatment, all patients underwent liver biopsy to detect HDV RNA in liver tissue.

Results. Out of 21 patients with sustained complete virological response (negative polymerase chain reaction result for HDV RNA in serum), 8 (38 %) had HDV RNA detected in liver tissue, indicating that a tissue virological response was not achieved. All 8 patients experienced a relapse of CHD within 24 weeks after discontinuing AVT.

Conclusions. In patients with chronic hepatitis D who have achieved a complete virological response in serum, the absence of a virological response in liver tissue (detection of HDV RNA in liver biopsy) is a predictor of relapse, providing a rationale for the continuation of antiviral therapy.

1. Kamal H., Westman G., Falconer K., Dube A.-S., Weiland O., Haverinen S., et al. Long-term study of hepati tis delta virus infection at secondary care centers: The impact of viremia on liver-related outcomes. Hepatology. 2020;72(4):1177–90. DOI: 10.1002/hep.31214

2. Urban S., Neumann-Haefelin C., Lampertico P. Hepatitis D virus in 2021: Virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. 2021;70(9):1782–94. DOI: 10.1136/gutjnl-2020-323888

3. Sausen D.G., Shechter O., Bietsch W., Shi Z., Mil ler S.M., Gallo E.O., et al. Hepatitis B and hepatitis D viruses: A comprehensive update with an immunological focus. Int J Mol Sci. 2022;23(24):15973. DOI: 10.3390/ijms232415973

4. Lombardo D., Franzè M.S., Caminiti G., Pollicino T. Hepatitis delta virus and hepatocellular carcinoma. Pathogens. 2024;13(5):362. DOI: 10.3390/pathogens13050362

5. Negro F., Lok A.S. Hepatitis D: A review. JAMA. 2023;330(24):2376–87. DOI: 10.1001/jama.2023.23242

6. Stockdale A.J., Kreuels B., Henrion M.Y.R., Gi orgi E., Kyomuhangi I., Martel C., et al. The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol. 2020;73(3):523–32. DOI: 10.1016/j.jhep.2020.04.008

7. Miao Z., Zhang S., Ou X., Li S., Ma Z., Wang W., et al. Estimating the global prevalence, disease progression, and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221(10):1677–87. DOI: 10.1093/infdis/jiz633

8. McNair A.N., Cheng D., Monjardino J., Thomas H.C., Kerr I.M. Hepatitis delta virus replication in vitro is not affected by interferon-alpha or -gamma despite intact cellular responses to interferon and dsRNA. J Gen Virol. 1994;75(Pt 6):1371–8. DOI: 10.1099/0022-1317-75-6-1371

9. Abdrakhman A., Ashimkhanova A., Almawi W.Y. Effectiveness of pegylated interferon monotherapy in the treatment of chronic hepatitis D virus infection: A meta-analysis. Antiviral Res. 2021;185:104995. DOI: 10.1016/j.antiviral.2020.104995

10. Bremer B., Anastasiou O.E., Hardtke S., Caruntu F.A., Curescu M.G., Yalcin K., et al. Residual low HDV viraemia is associated HDV RNA relapse after PEG-IFNa-based antiviral treatment of hepatitis delta: Results from the HIDIT-II study. Liver Int. 2021;41(2):295–9. DOI: 10.1111/liv.14740

11. Wedemeyer H., Yurdaydìn C., Dalekos G.N., Erhardt A., Çakaloğlu Y., Değertekin H., et al.; HIDIT Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364(4):322–31. DOI: 10.1056/NEJMoa0912696

12. Brancaccio G., Fasano M., Grossi A., Santantonio T.A., Gaeta G.B. Clinical outcomes in patients with hepatitis D, cirrhosis and persistent hepatitis B virus replication, and receiving long-term tenofovir or entecavir. Aliment Pharmacol Ther. 2019;49(8):1071–6. DOI: 10.1111/apt.15188

13. Urban S., Bartenschlager R., Kubitz R., Zoulim F. Strategies to inhibit entry of HBV and HDV into hepatocytes. Gastroenterology. 2014;147(1):48–64. DOI: 10.1053/j.gastro.2014.04.030

14. Blank A., Eidam A., Haag M., Hohmann N., Burhenne J., Schwab M., et al. The NTCP-inhibitor Myrcludex B: Effects on bile acid disposition and tenofovir pharmacokinetics. Clin Pharmacol Ther. 2018;103(2):341–8. DOI: 10.1002/cpt.744

15. Bogomolov P., Alexandrov A., Voronkova N., Macievich M., Kokina K., Petrachenkova M., et al. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study. J Hepatol. 2016;65(3):490–8. DOI: 10.1016/j.jhep.2016.04.016

16. Dietz-Fricke C., Tacke F., Zöllner C., Demir M., Schmidt H.H., Schramm C., et al. Treating hepatitis D with bulevirtide — real-world experience from 114 patients. JHEP Rep. 2023;5(4):100686. DOI: 10.1016/j.jhepr.2023.100686

17. Allweiss L., Volmari A., Suri V., Wallin J.J., Flaherty J.F., Manuilov D., et al. Blocking viral en try with bulevirtide reduces the number of HDV infected hepatocytes in human liver biopsies. J Hepatol. 2024;80(6):882–91. DOI: 10.1016/j.jhep.2024.01.035

18. Wedemeyer H., Leus M., Battersby T.R., Glenn J., Gordien E., Kamili S., et al. HDV RNA assays: Performance characteristics, clinical utility and challenges. Hepatology. 2023;10.1097/HEP.0000000000000584. DOI: 10.1097/HEP.0000000000000584

19. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines on hepatitis delta virus. J Hepatol. 2023;79(2):433– 60. DOI: 10.1016/j.jhep.2023.05.001

20. Queiroz J.A., Roca T.P., Souza R.B., Fellype L., Alves de Souza L.F., Passos-Silva A., et al. Development of quantitative multiplex RT-qPCR one step assay for detection of hepatitis delta virus. Sci Rep. 2023;13(1):12073. DOI: 10.1038/s41598-023-37756-z

21. Jachs M., Panzer M., Hartl L., Schwarz M., Bal car L., Camp J.V., et al. Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression. JHEP Rep. 2023;5(8):100751. DOI: 10.1016/j.jhepr.2023.100751